Monitoring Heart Rate Variability for the Early Detection of Pancreatic Cancer

OHSU Knight Cancer Institute

Status

Terminated

Conditions

Stage IA Pancreatic Cancer AJCC v8

Stage I Pancreatic Cancer AJCC v8

Stage IB Pancreatic Cancer AJCC v8

Pancreatic Ductal Adenocarcinoma

Treatments

Other: Quality-of-Life Assessment

Other: Questionnaire Administration

Device: Activity Monitor

Study type

Observational

Funder types

Other

NIH

Identifiers

NCT04400903

R01CA264133 (U.S. NIH Grant/Contract)

NCI-2020-03178 (Registry Identifier)

STUDY00021185 (Other Identifier)

Details and patient eligibility

About

This study examines heart rate monitoring variability for the early detection of pancreatic cancer. Pancreatic cancer is a very difficult disease to detect early. This study is being done to observe the heart rate variability in patients with pancreatic cancer compared to undiagnosed individuals with increased risk of developing pancreatic cancer. This may help researchers determine if pancreatic occurrences/recurrences (chance of coming back) can be detected sooner through monitoring heart rate and activity.

Full description

PRIMARY OBJECTIVES:

I. To determine whether heart rate variability (HRV) is reduced in patients with pancreatic ductal adenocarcinoma (PDAC) compared with individuals at increased risk of developing PDAC. (Stage I) II. To assess the feasibility of long-term compliance using a wearable device. (Stage II)

SECONDARY OBJECTIVES:

I. To assess compliance with using a wearable device. (Stage I and II) II. To validate effectiveness of virtual device training. (Stage I and II) III. To determine whether HRV is reduced in participants at high-risk of developing PDAC. (Stage II) IV. To characterize timing and occurrence of PDAC among high-risk without disease. (Stage II) V. To characterize timing and occurrence of PDAC among participants at high-risk of developing PDAC. (Stage II)

EXPLORATORY OBJECTIVES:

I. To investigate the relationship between changes in HRV relative to sarcopenia-related body composition characteristics in PDAC patients. (Stage I) II. To investigate the relationship between the pNN50 HRV measure and PDAC diagnosis. (Stage I and II) III. To compare changes in sleep biometrics among all participants. (Stage I and II) IV. To evaluate changes in health-related quality of life assessments among all participants. (Stage I and II) V. To evaluate participant satisfaction with virtual device instruction.

OUTLINE:

Participants undergo HRV monitoring using an activity monitor (WHOOP) for a minimum of 5 days weekly for up to 1 year in patients with newly-diagnosed PDAC and up to 5 years for patients in high risk group.

Enrollment

110 patients

Sex

All

Ages

50 to 75 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Ability to understand and the willingness to sign an informed consent document
Own a smartphone that uses Android or Apple iOS operating systems
Participant must have one of the following:
- Individuals with newly-diagnosed, treatment naive PDAC - all stages (applicable to Stage 1 only), or
- Individuals with at least one of the following family phenotype and age will be included:
  - Two or more relatives with PDAC on the same side of the family, where 2 PDAC affected individuals are first-degree related (FDR) AND at least one PDAC-affected individual is an FDR of the subject; Age >= 50 years OR 10 years before onset in family
  - Two affected FDR with PDAC; Age >= 50 years OR 10 years before onset of an FDR
  - Any of BRCA1, BRCA2, PALB2, ATM mutations confirmed pathogenic or likely pathogenic; Age >= 50 years OR 10 years before onset of an FDR or second-degree relative (SDR)
  - Familial atypical multiple mole-melanoma (FAMMM) with confirmed pathogenic or likely pathogenic mutation variants in: p16, CDKN2A; Age >= 50 years
  - Known mutation carrier for STK11 (Peutz-Jeghers syndrome); Age >= 50 years
  - Lynch syndrome (hereditary nonpolyposis colorectal cancer [HNPCC]) with confirmed pathogenic or likely pathogenic variants in: MLH1, MSH2, MSH6, PMS2, or EPCAM; Age >= 50 years OR 10 years before onset of an FDR or SDR
  - Hereditary pancreatitis with confirmed PRSS1 pathogenic or likely pathogenic history of pancreatitis; Age >= 50 years